2021 Revenues ($USD) : $6,304,000,000
2021 R&D spend : $443,000,000
2021 Number of Employees : 9,500
Fiscal Year End : 12/31/2021
Leader : CEO Kevin Ali

Organon was founded in 1923 to produce insulin. The company in 2007 became part of Schering-Plough, which merged with Merck & Co. in 2009. In June 2021, Merck & Co. completed its spinoff of Organon. The three pillars of its current business include women’s health, biosimilars and established medicines. In 2021, its revenue was $6.3 billion, with the Nexplanon (etonogestrel implant), fertility and biosimilars fueling the bulk of its growth. The company’s established brands portfolio includes 49 products. Organon also has a significant presence in China, where it derives about one-fifth of its established brands revenue. The company also has a growing biosimilars business. —BB